Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...

Trade deficit data, Federal Reserve officials' remarks, earnings from Pfizer, Disney, Uber, and additional companies.

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to ...

President Donald Trump just sent letters to heads of 17 major pharmaceutical companies pushing them to drop drug prices in ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

VHT is attractively valued at 16x forward earnings, but sector momentum is weak and technicals remain bearish. Read why VHT ...

As Wall Street embarks on the first full week of August, the earnings wave continues with another stacked week of reports ...

Novo Nordisk has reported another significant criticality: the presence of unauthorized versions of its drugs on the US ...

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

Concerns over US economic growth have taken center stage despite a solid corporate earnings season from S&P 500 companies.

People taking weight loss drugs typically start to lose weight within a few weeks. One study, funded by Mounjaro manufacturer ...